ARAnna Rowe

Anna Rowe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Rowe has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Feasibility of a new electronic patient-reported outcome (ePRO) system for an advanced therapy clinical trial in immune-mediated inflammatory disease: the PROmics system (Preprint)

    by Christel McMullan, Sarah E Hughes, Anna L Rowe, Ameeta Retzer, Camilla Bathurst, Rosie Harding, Derek Kyte, Elin Haf Davies, Roger Wilson, Philip N Newsome, et al.

    BACKGROUND Advanced therapy medicinal products (ATMPs) are increasingly evaluated in early-phase clinical trials, where understanding patient-reported symptoms, tolerability, and health-related quality of life is critical. Electronic patient-reported outcome (ePRO) systems offer potential advantages over paper-based methods, but evidence on their feasibility and acceptability in ATMP trials remains limited. OBJECTIVE To assess the feasibility and acceptability of the PROmics ePRO system when deployed within a phase II, multi-disease ATMP clinical trial involving patients with immune-mediated inflammatory diseases. METHODS A qualitative interview-based feasibility study was embedded within the POLARISE trial, a multicentre phase II ATMP basket trial investigating ORBCEL-C™ in patients with rheumatoid arthritis, primary sclerosing cholangitis, Crohn’s disease, and lupus nephritis. Semi-structured interviews were conducted with trial participants and research and clinical staff who used the PROmics system. Interviews explored experiences of training, usability, questionnaire burden, real-time alerts, and integration within trial workflows. Transcripts were thematically analysed using the framework method. RESULTS Fourteen participants were interviewed (seven patients and seven staff). Overall, the PROmics system was perceived as acceptable, intuitive, and easy to use by both patients and staff. Automated reminders and real-time alerts were key facilitators of engagement and provided reassurance to patients that their symptoms were actively monitored. However, several feasibility challenges were identified, including technical issues, uncertainty around support pathways, questionnaire burden, and the workload associated with managing alerts. Staff turnover and limitations in clinical dashboard usability and system integration further increased implementation burden. CONCLUSIONS The PROmics ePRO system was acceptable and valued by patients and staff in the context of an ATMP trial, but successful implementation requires careful attention to technical stability, user support, questionnaire scheduling, and alert management within existing trial infrastructure. Addressing these issues is essential to maximise the feasibility, sustainability, and value of digital PROM collection in future ATMP clinical trials. CLINICALTRIAL n/a INTERNATIONAL REGISTERED REPORT RR2-10.1136/bmjopen-2022-063199

  • Open Access

    Addition of a dendritic cell vaccine to conditioning cyclophosphamide and chemoembolisation to prolong progression-free survival in patients with hepatocellular carcinoma: the ImmunoTACE RCT

    by Yuk Ting Ma, Amanda Kirkham, Stuart Curbishley, Anna Rowe, Jessica Douglas-Pugh, Camilla Bathurst, Manpreet Wilkhu, Homoyoon Mehrzad, Salil Karkhanis, Martin James, et al.

    Background: A previous study by our group using dendritic cells pulsed ex vivo with the lysate of the HepG2 cell line showed clinical benefit with evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. This trial set out to investigate the activity of this vaccine in combination with chemoembolisation compared to chemoembolisation alone in patients with intermediate stage hepatocellular carcinoma. All patients also received a conditioning regimen comprising low-dose cyclophosphamide. Objectives: To determine whether the addition of a dendritic cell vaccine to chemoembolisation and preconditioning cyclophosphamide prolongs progression-free survival and warrants further investigation. Design: Multicentre, open-label, randomised Phase II trial. Setting: Three tertiary referral units in the United Kingdom: Queen Elizabeth Hospital, Birmingham; Aintree University Hospital/Clatterbridge Cancer Centre, Liverpool and Queen’s Medical Centre, Nottingham. Participants: Patients > 18 years with intermediate stage hepatocellular carcinoma, performance status 0–2 and Child–Pugh A/B7 liver function. Intervention: Preconditioning cyclophosphamide on Day 1 and Day 29 followed by chemoembolisation on Day 31 (± dendritic cell infusion), followed by further preconditioning cyclophosphamide on Days 60, 90 and 120 (± additional dendritic cell infusions on Days 62, 92 and 122). Main outcome measures: The primary endpoint was progression-free survival time using Response Evaluation Criteria in Solid Tumours v1.1 criteria. Secondary endpoints were progression-free survival time based on modified (m) Response Evaluable Criteria in Solid Tumours criteria, overall survival time, radiological response according to Response Evaluable Criteria in Solid Tumours 1.1 criteria, radiological response based on Modified Response Evaluable Criteria in Solid Tumours criteria, change in the serum alpha-fetoprotein tumour marker, toxicity using Common Terminology Criteria for Adverse Events v4.0 and immune response. Results: Between March 2016 and October 2019, 55 patients were randomised of whom 48 are evaluable (24 in each group). The progression-free survival time using Response Evaluable Criteria in Solid Tumours criteria was 18.6 months in patients treated with chemoembolisation plus preconditioning cyclophosphamide plus dendritic cell infusions (Group 2) compared to 10.4 months in those treated with chemoembolisation plus preconditioning cyclophosphamide alone (Group 1) (hazard ratio 0.43, upper value of one-sided 80% confidence interval 0.57; p = 0.016). Although not statistically powered, the progression-free survival time using Modified Response Evaluable Criteria in Solid Tumours criteria showed a similar magnitude of benefit (18.6 vs 10.8 months: hazard ratio 0.48, 95% confidence interval 0.22 to 1.02). The overall response rate (complete response and partial response) by Response Evaluable Criteria in Solid Tumours was 54% in Group 2 and 29% in Group 1 and the disease control rate (complete response, partial response and stable disease) was 92% in Group 2 and 67% in Group 1. Treatment with dendritic cell vaccination was associated with an enhanced antigen-specific immune response. Treatment was well tolerated with few additional adverse events from the additional dendritic cell infusions. Conclusions: Chemoembolisation plus preconditioning cyclophosphamide plus dendritic cell infusions merit further investigation in a randomised Phase III trial but the trial design will need to take into account the current evolving hepatocellular carcinoma treatment landscape. Limitations: The current dendritic cell manufacturing process limits large-scale use and further validation and automation of the process will be needed prior to testing in a randomised Phase III trial. Future Work: Further testing in a randomised Phase III trial is warranted. Trial registration: This trial is registered as ISRCTN11889464; EudraCT number: 2011-001690-62. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 09/160/24) and is published in full in Efficacy and Mechanism Evaluation; Vol. 12, No. 9. See the NIHR Funding and Awards website for further award information.

  • Open Access

    Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial

    by Yuk Ting Ma, Jianmin Zuo, Amanda Kirkham, Stuart Curbishley, Miroslava Blahova, Anna L. Rowe, Camilla Bathurst, Homoyoon Mehrzad, Salil Karkhanis, Pankaj Punia, et al.

    Purpose: A previous study by our group using dendritic cells (DC) pulsed ex vivo with the lysate of the HepG2 cell line showed evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. The ImmunoTACE trial evaluated the preliminary activity of this vaccine in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma. Patients and Methods: A randomized phase II trial was conducted in three tertiary referral centers in the United Kingdom. Eligible patients were randomly assigned in a 1:1 ratio to TACE + preconditioning cyclophosphamide or to TACE + preconditioning cyclophosphamide + DC infusions. The primary endpoint was progression-free survival time using RECIST v1.1 criteria. Additional endpoints included safety and immune responses. Results: Between March 2016 and October 2019, 55 patients were randomized, of whom 48 were evaluable (24 in each group). The median progression-free survival time using RECIST criteria was 18.6 months in patients treated with chemoembolization + preconditioning cyclophosphamide + DC infusions compared with 10.4 months in those treated with chemoembolization + preconditioning cyclophosphamide alone (HR = 0.43; upper value of one-sided 80% confidence interval, 0.57; P = 0.016). The addition of DC infusions did not significantly increase the incidence or severity of adverse events. An enhanced antigen (α-fetoprotein)-specific immune response was observed in patients treated with DC vaccination. Conclusions: The addition of DC infusions to TACE and preconditioning cyclophosphamide has shown promising preliminary activity and merits further investigation in a larger randomized trial.


  • Open Access

    Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial

    by Gideon M. Hirschfield, Katherine Arndtz, Amanda Kirkham, Yung-Yi Chen, Richard Fox, Anna Rowe, Jessica Douglas-Pugh, Douglas Thorburn, Eleanor Barnes, Guruprasad P. Aithal, et al.

    Background: Primary sclerosing cholangitis is a progressive inflammatory liver disease characterized by biliary and liver fibrosis. Vascular adhesion protein-1 (VAP-1) is important in the inflammatory process driving liver fibrosis. We evaluated the safety and efficacy of VAP-1 blockade with a monoclonal antibody (timolumab, BTT1023) in patients with primary sclerosing cholangitis. Methods: BUTEO was a prospective, single-arm, open-label, multicenter, phase II trial, conducted in 6 centers in the United Kingdom. Patients with primary sclerosing cholangitis aged 18–75 years had an alkaline phosphatase value of >1.5 times the upper limit of normal. The dose-confirmatory stage aimed to confirm the safety of timolumab through the incidence of dose-limiting toxicity and sufficient trough levels of circulating antibody to block VAP-1 function. The primary outcome of the dose-expansion portion of the trial was patient’s response to timolumab at day 99, as measured by a reduction in serum alkaline phosphatase by 25% or more from baseline to day 99. Results: Twenty-three patients were recruited: 7 into the initial dose-confirmatory stage and a further 16 into an expansion stage. Timolumab (8 mg/kg) was confirmed to be safe for the duration of administration with sufficient circulating levels. Only 2 of the 18 evaluable patients (11.1%) achieved a reduction in alkaline phosphatase levels of 25% or more, and both the proportion of circulating inflammatory cell populations and biomarkers of fibrosis remained unchanged from baseline. Conclusions: The BUTEO trial confirmed 8 mg/kg timolumab had no short-term safety signals and resulted in sufficient circulating levels of VAP-1 blocking timolumab. However, the trial was stopped after an interim assessment due to a lack of efficacy as determined by no significant change in serum liver tests.


  • Open Access

    Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial

    by Katherine Arndtz, Yung-Yi Chen, Anna Rowe, Victoria Homer, Amanda Kirkham, Jessica Douglas-Pugh, Daniel Slade, Douglas Thorburn, Eleanor Barnes, Guruprasad Aithal, et al.

    Background: Primary sclerosing cholangitis is a progressive and fibrotic liver disease. Treatments remain inadequate, and patients with persistent elevations in activity of alkaline phosphatase are at greatest risk of disease progression. Studies in patient cohorts have implicated the serum amine oxidase vascular adhesion protein 1 in the pathophysiology of disease, including liver fibrogenesis. We hypothesised that blockade of serum amine oxidase by a monoclonal antibody would result in a reduction in liver fibrosis/injury, as evaluated by serum liver tests and other non-invasive markers of liver injury. Objectives: To evaluate the open-label effect on liver injury markers of treatment with the anti-vascular adhesion protein 1 monoclonal antibody BTT1023 in patients with primary sclerosing cholangitis over a 78-day treatment period. Design: A single-arm, two-stage, open-label, multicentre, Phase II clinical trial. Setting: Ambulatory liver disease practices in tertiary care hospitals. Participants: Patients with primary sclerosing cholangitis at risk of disease progression, based on elevated activity of serum alkaline phosphatase, and without evidence of infection, liver failure or advanced disease. Intervention: Seven intravenous infusions of BTT1023 (8 mg/kg of timolumab) over a 78-day treatment period. The intervention was split into a dose-confirmatory stage (to confirm pharmacokinetics), followed by a confirmed expansion cohort stage. Main outcome measures: Our primary outcome measure was patient response to treatment at day 99, measured by a reduction in activity of serum alkaline phosphatase of ≥ 25% from baseline to day 99. Secondary markers of efficacy were assessed based on evaluation of changes in markers of liver injury and liver fibrosis. Safety assessments were performed throughout. Results: Thirty-five patients were consented and screened for eligibility. Twenty-three patients were treated across the two stages of the trial. Interim assessment demonstrated a failure to meet the primary end point, leading to trial discontinuation on the grounds of futility. Multiple exploratory markers were evaluated in a final cohort of 22 patients (modified intention-to-treat analysis). No treatment-related effects were evident. No new safety concerns were seen. Conclusions: No preliminary evidence for disease modification was demonstrated. Limitations: It is clear that this study is limited in its design. Even if there were a better biomarker of fibrosis turnover that could be considered the ‘gold standard’, the design and duration would have had real-world resource limitations. With limited opportunity to test a new agent in large numbers of patients over a prolonged period, it was necessary to aim to see efficacy in a small cohort over a short period. Given the absence of any proven biochemical surrogate of disease activity in primary sclerosing cholangitis, alkaline phosphatase was chosen as an end point. This remains a difficult end point (yet one that does capture biliary injury) and, therefore, despite limitations, this study did demonstrate short-term safety. Future work: Future research will require attention to an ongoing debate regarding the optimal end points for assessing efficacy, as well as consideration of duration of treatment, even in early-phase studies. This raises the challenge of how to fund early experimental trials with ‘high risk of failure’ adequately to ensure that clearer results (negative or positive) arise by the end of the study. Trial registration: Current Controlled Trials ISRCTN11233255, EudraCT 2014-002393-37 and NCT02239211. Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be published in full in Efficacy and Mechanism Evaluation; Vol. 9, No. 1. See the NIHR Journals Library website for further project information.